Valuation: Rani Therapeutics Holdings, Inc.

Market Cap 77.06M 67.49M 62.16M 57.7M 110M 7.35B 111M 744M 290M 3.61B 289M 283M 12.51B P/E 2026 *
-3.99x
P/E 2027 * -3.51x
Enterprise Value 77.06M 67.49M 62.16M 57.7M 110M 7.35B 111M 744M 290M 3.61B 289M 283M 12.51B EV / Sales 2026 *
18.7x
EV / Sales 2027 * 15.6x
Free-Float
78.3%
Yield 2026 *
-
Yield 2027 * -
1 day+2.81%
1 week+3.70%
Current month+4.29%
1 month-5.55%
3 months-4.47%
6 months-42.54%
Current year-41.26%
1 week 0.75
Extreme 0.7477
0.83
1 month 0.72
Extreme 0.72
0.85
Current year 0.68
Extreme 0.68
1.54
1 year 0.39
Extreme 0.387
3.87
3 years 0.39
Extreme 0.387
8.75
5 years 0.39
Extreme 0.387
36.27
10 years 0.39
Extreme 0.387
36.27
Manager TitleAgeSince
Chief Executive Officer 45 2021-05-31
Director of Finance/CFO 46 2026-06-28
Chief Tech/Sci/R&D Officer 42 2021-12-31
Director TitleAgeSince
Chairman 69 2021-05-31
Director/Board Member 80 2018-08-31
Director/Board Member 69 2021-04-05
Date Insider Type Main position Quantity % Market Cap.
06-02Free

Chief Technology Officer

805,500 0.8077%
06-02Free

Founder

3,800,000 3.8106%
06-02Free

Executive/Senior Manager

805,500 0.8077%
Change 5-day change 1-year change 3-year change Capi.($)
+2.81%+3.70%+47.87%-81.12% 77.06M
-2.14%+3.65%+74.05%+131.89% 59.1B
-0.93%+4.05%+73.64%+90.53% 55.19B
-3.71%-0.35%-14.65%-11.19% 24.67B
-0.05%+6.49%+15.05%+451.36% 24.19B
+0.64%+14.41%+44.27%-3.20% 19.69B
-2.19%+7.37%+40.74%-30.67% 17.56B
+3.58%+25.11%+196.41%+363.46% 16.22B
+4.91%+25.24%+44.61% - 14.84B
-0.57%+2.30%+25.75%+187.27% 14.04B
Average +0.34%+7.94%+54.77%+122.04% 24.56B
Weighted average by Cap. -0.59%+6.43%+58.00%+135.87%

Financials

2026 *2027 *
Net sales 4.13M 3.61M 3.33M 3.09M 5.87M 394M 5.95M 39.86M 15.51M 193M 15.5M 15.16M 670M 4.92M 4.31M 3.97M 3.69M 7M 470M 7.1M 47.56M 18.51M 231M 18.5M 18.09M 800M
Net income -33.21M -29.09M -26.79M -24.87M -47.23M -3.17B -47.86M -321M -125M -1.56B -125M -122M -5.39B -39.93M -34.97M -32.21M -29.9M -56.77M -3.81B -57.54M -386M -150M -1.87B -150M -147M -6.48B
Net Debt - -
Logo Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
Employees
70
Date Price Change Volume
26-07-06 US$0.7930 +2.81% 949,606
26-07-02 US$0.7713 +0.38% 504,534
26-07-01 US$0.7684 +1.05% 473,116
26-06-30 US$0.7604 -0.56% 213,003
26-06-29 US$0.7647 +3.91% 545,525
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.7713USD
Average target price
7.500USD
Spread / Average Target
+872.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RANI Stock